CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 57 filers reported holding CITIUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $721,539 | -41.5% | 1,054,265 | +2.5% | 0.00% | – |
| Q2 2023 | $1,234,387 | +330.2% | 1,028,656 | +319.4% | 0.00% | – |
| Q1 2023 | $286,932 | +52.5% | 245,241 | +2.9% | 0.00% | – |
| Q4 2022 | $188,204 | -34.9% | 238,233 | 0.0% | 0.00% | – |
| Q3 2022 | $289,000 | +31.4% | 238,233 | -0.2% | 0.00% | – |
| Q2 2022 | $220,000 | -88.4% | 238,693 | -77.6% | 0.00% | – |
| Q1 2022 | $1,904,000 | +23.7% | 1,063,417 | +6.4% | 0.00% | – |
| Q4 2021 | $1,539,000 | -25.9% | 999,865 | -2.2% | 0.00% | – |
| Q3 2021 | $2,076,000 | -54.1% | 1,022,548 | -21.3% | 0.00% | -100.0% |
| Q2 2021 | $4,519,000 | +1041.2% | 1,298,509 | +484.3% | 0.00% | – |
| Q1 2021 | $396,000 | +401.3% | 222,246 | +188.5% | 0.00% | – |
| Q4 2020 | $79,000 | +79.5% | 77,026 | +83.9% | 0.00% | – |
| Q3 2020 | $44,000 | +25.7% | 41,875 | +33.9% | 0.00% | – |
| Q2 2020 | $35,000 | +250.0% | 31,267 | +84.5% | 0.00% | – |
| Q1 2020 | $10,000 | – | 16,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |